Last reviewed · How we verify
Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| azelastine hydrochloride 0.05% | azelastine hydrochloride 0.05% | marketed | H1-receptor antagonist (second-generation antihistamine) | H1 receptor | Allergy/Immunology |
Therapeutic area mix
- Allergy/Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AAADRS Clinical Research Center · 1 shared drug class
- Brian J Lipworth · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- Goldman, Butterwick, Fitzpatrick and Groff · 1 shared drug class
- HK inno.N Corporation · 1 shared drug class
- Organon and Co · 1 shared drug class
- UCB Pharma · 1 shared drug class
- University Hospital, Grenoble · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona:
- Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona pipeline updates — RSS
- Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona pipeline updates — Atom
- Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azienda-ospedaliera-oo-rr-s-giovanni-di-dio-e-ruggi-d-aragona. Accessed 2026-05-17.